There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Paragon 28 (FNA – Research Report) and Caribou Biosciences (CRBU – Research Report) with bullish sentiments.
Paragon 28 (FNA)
In a report released yesterday, Craig Bijou from Bank of America Securities reiterated a Buy rating on Paragon 28, with a price target of $15.00. The company’s shares closed last Thursday at $10.20.
According to TipRanks.com, Bijou is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Paragon 28 with a $18.00 average price target, which is a 51.0% upside from current levels. In a report issued on March 28, Needham also reiterated a Buy rating on the stock with a $17.00 price target.
See the top stocks recommended by analysts >>
Caribou Biosciences (CRBU)
Bank of America Securities analyst Geoff Meacham maintained a Buy rating on Caribou Biosciences yesterday and set a price target of $17.00. The company’s shares closed last Thursday at $4.54.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of
Caribou Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $22.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on FNA:
